title: High prevalence of antibody to hepatitis C virus in heavy drinkers with chronic liver diseases in Japan.
abstract: To investigate the prevalence of antibody to hepatitis C virus (anti-HCV) in heavy drinkers with liver disease in Japan, we tested serum samples from 113 heavy drinkers with liver disease and 121 without liver disease. All were negative for HBsAg with no history of blood transfusion. These subjects had consumed more than 80 g of ethanol daily for 5 years or more. Findings for anti-HCV determined by recombinant immunoblot assay testing were positive in 14 (35.9%) of the 39 patients with liver cirrhosis, 14 (58.3%) of the 24 patients with hepatocellular carcinoma and in 8 (53.3%) of the 15 patients with chronic hepatitis. The anti-HCV positive rate in the drinkers with these liver diseases was significantly higher than in those with such disorders as fatty liver (0/10), hepatic fibrosis (0/22), and alcoholic hepatitis (0/3), as well as in the alcoholics without liver disease (5/121, 4.2%). Considering histologic findings in the anti-HCV positive cirrhotics, the occurrence of lymph follicle formation (71.4%), piecemeal necrosis (78.6%) and loose fibrosis (64.3%) were observed to a significantly higher extent than in cirrhotics who were negative for anti-HCV. These findings suggest that advanced chronic liver disease among heavy drinkers in Japan, especially of hepatocellular carcinoma, is closely associated with HCV infection. In the livers of heavy drinkers who were positive for anti-HCV, histologic findings indicated the possibility of viral infection.
authors.affiliation: Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Shimizu
authors.forename: K
authors.initials: K
authors.lastname: Kiyosawa
authors.forename: T
authors.initials: T
authors.lastname: Sodeyama
authors.forename: E
authors.initials: E
authors.lastname: Tanaka
authors.forename: M
authors.initials: M
authors.lastname: Nakano
mesh_terms: D000328:Adult; D000368:Aged; D000437:Alcoholism / Q000150:complications / Q000276:immunology / Q000382:microbiology; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000276:immunology / Q000382:microbiology / Q000473:pathology; D005260:Female; D016174:Hepacivirus / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000032:analysis*; D006519:Hepatitis, Alcoholic / Q000276:immunology / Q000382:microbiology / Q000473:pathology; D006801:Humans; D007564:Japan; D008099:Liver / Q000473:pathology; D008104:Liver Cirrhosis, Alcoholic / Q000276:immunology / Q000382:microbiology / Q000473:pathology; D008108:Liver Diseases, Alcoholic / Q000276:immunology / Q000382:microbiology* / Q000473:pathology; D008113:Liver Neoplasms / Q000150:complications / Q000276:immunology / Q000382:microbiology / Q000473:pathology; D008297:Male; D008875:Middle Aged
chemical_list: D006508:Hepatitis Antibodies